Vandetanib plus pemetrexed for the second-line treatment of advanced non - small-cell lung cancer: A randomized, double-blind phase III trial

Richard H. De Boer, Óscar Arrieta, Chih Hsin Yang, Maya Gottfried, Valorie Chan, Johann Raats, Filippo De Marinis, Raymond P. Abratt, Jürgen Wolf, Fiona H. Blackhall, Peter Langmuir, Tsveta Milenkova, Jessica Read, Johan F. Vansteenkiste

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed as second-line therapy in advanced non - small-cell lung cancer. Patients and Methods: Patients (N = 534) were randomly assigned to receive vandetanib 100 mg/d plus pemetrexed 500 mg/m2 every 21 days (n = 256) or placebo plus pemetrexed (n = 278). Progression-free survival (PFS) was the primary end point; overall survival, objective response rate, disease control rate, time to deterioration of symptoms, and safety were secondary assessments. Results: There was no significant difference in PFS between treatment arms (hazard ratio [HR], 0.86; 97.58% CI, 0.69 to 1.06; P = .108). Overall survival was also not significantly different (HR, 0.86; 97.54% CI, 0.65 to 1.13; P = .219). Statistically significant improvements in objective response rate (19% v 8%; P <.001) and time to deterioration of symptoms (HR, 0.71; P = .0052; median, 18.1 weeks for vandetanib and 12.1 weeks for placebo) were observed in patients receiving vandetanib. Adding vandetanib to pemetrexed increased the incidence of some adverse events, including rash, diarrhea, and hypertension, while showing a reduced incidence of nausea, vomiting, anemia, fatigue, and asthenia with no reduction in the dose intensity of pemetrexed. Conclusion: This study did not meet the primary end point of statistically significant PFS prolongation with vandetanib plus pemetrexed versus placebo plus pemetrexed. The vandetanib combination showed a significantly higher objective response rate and a significant delay in the time to worsening of lung cancer symptoms versus the placebo arm as well as an acceptable safety profile in this patient population.

Original languageEnglish
Pages (from-to)1067-1074
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number8
DOIs
Publication statusPublished - Mar 10 2011

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Vandetanib plus pemetrexed for the second-line treatment of advanced non - small-cell lung cancer: A randomized, double-blind phase III trial'. Together they form a unique fingerprint.

Cite this